

between the two studies. The number of patients who had severe IR who were enrolled in our study (four of 74, 5.4%) was smaller than that in Akuta's study (13 of 34, 38.2%), although three of our four patients with severe IR (HOMA-IR \geq 3.5) showed core aa 70 substitutions. Akuta *et al.* have also reported that substitutions of the HCV-1b core region are not an important predictor of IR (HOMA-IR \geq 2.5). Third, the method to assess IR was different between the two studies. Most studies have reported on the correlations between HCV infection and hepatic IR using the HOMA-IR index, as in the study of Akuta *et al.* Recently, some researchers^{25,41-43} have reported that some indices obtained from OGTT could be useful for the evaluation of systemic glucose metabolism. These indices include PG-AUC, SI-AUC and ISI composite.^{25,41} In particular, the ISI composite is highly correlated with the rate of whole-body glucose disposal during euglycemic insulin clamping. As IR develops simultaneously in multiple organs and cells, including the liver, skeletal muscle and adipocytes, it is necessary to investigate the association between HCV infection and systemic glucose metabolism using these indices. Unexpectedly, in our study, evaluation of IR or glucose tolerance by carrying out the 75-g OGTT, PG-AUC, SI-AUC and ISI composite did not differ between patients with and without core amino acid substitutions (Fig. 2). To the best of our knowledge, our study is the first to examine the correlations between substitutions of core amino acids and glucose tolerance evaluated with the 75-g OGTT. Thus, further studies based on a large number of patients should be carried out in the future.

The other factor that was related to liver steatosis was glucose intolerance rather than IR. Controversial results concerning the correlations between IR and hepatic steatosis exist. Fartoux *et al.* have revealed an association of IR with hepatic steatosis in non-diabetic, non-cirrhotic patients with HCV genotype 1.⁴⁴ In contrast, according to Tachi *et al.*,³⁹ IR that was evaluated by HOMA-IR was not selected as a parameter to predict hepatic steatosis. In transgenic mice that express HCV core protein, Shintani *et al.* has shown that IR precedes the occurrence of steatosis, which suggests that IR is not a consequence but a cause of hepatic steatosis.⁹ The mechanisms of development of IR in patients with chronic HCV infection are not well understood. It is plausible that HCV itself has a direct role in the development of IR, as recently reported by clinical and experimental studies.^{9-11,13} HCV seems to lead to IR through interference of intracellular insulin signaling by HCV proteins, mainly the serine phosphorylation of insulin receptor-1 (IRS-1) and impairment of the downstream Akt signaling pathway. A high level of tumor necrosis factor α , which has been observed in CHC patients, is considered to act by disturbing tyrosine phosphorylation of IRS-1. Our results suggest that hyperglycemia has an important role in hepatic steatosis. Glucose activates the nuclear transcription factor carbohydrate response element-binding protein (ChREBP), by upregulating the conversion of glucose into pyruvate by increasing the expression of L-pyruvate, a glycolysis rate-limiting enzyme. ChREBP also increases transcription of the lipogenic enzyme acetyl CoA carboxylase and fatty acid synthase genes. High blood glucose levels further enhance hepatic lipogenesis by ChREBP activation, hence increasing the hepatic expression of all hepatic lipogenic genes.⁴⁵

In conclusion, the results of the present study indicated that substitutions of HCV-1b core region besides glucose intolerance were an important predictor of steatosis in patients without cir-

rhosis and overt diabetes mellitus. The cause of steatosis in CHC with HCV genotype 1 can be split into viral factors (substitutions of core aa 70), and host factors (glucose tolerance). Substitution of core amino acids does not seem to influence glucose tolerance or IR.

Acknowledgments

This study was presented at the 61st annual meeting of the American Association for the Study of Liver Diseases (AASLD) on 31 October 2010.⁴⁶

References

- 1 Cross TJ, Rashid MM, Berry PA, Harrison PM. The importance of steatosis in chronic hepatitis C infection and its management: a review. *Hepatol. Res.* 2010; **40**: 237-47.
- 2 Westin J, Nordlinder H, Lagging M *et al.* Steatosis accelerates fibrosis development over time in hepatitis C virus genotype 3 infected patients. *J. Hepatol.* 2002; **37**: 837-42.
- 3 Fujie H, Yotsuyanagi H, Moriya K *et al.* Steatosis and intrahepatic hepatitis C virus in chronic hepatitis. *J. Med. Virol.* 1999; **59**: 141-5.
- 4 Lonardo A, Adinolfi LE, Loria P *et al.* Steatosis and hepatitis C virus: mechanisms and significance for hepatic and extrahepatic disease. *Gastroenterology* 2004; **126**: 586-97.
- 5 Sumida Y, Kanemasa K, Fukumoto K *et al.* Correlation of hepatic steatosis with body mass index, serum ferritin level and hepatic fibrosis in Japanese patients with chronic hepatitis C. *Hepatol. Res.* 2007; **37**: 263-9.
- 6 Mason AL, Lau JY, Hoang N *et al.* Association of diabetes mellitus and chronic hepatitis C virus infection. *Hepatology* 1999; **29**: 328-33.
- 7 Caronia S, Taylor K, Pagliaro L *et al.* Further evidence for an association between non-insulin-dependent diabetes mellitus and chronic hepatitis C virus infection. *Hepatology* 1999; **30**: 1059-63.
- 8 Mehta SH, Brancati FL, Sulkowski MS *et al.* Prevalence of type 2 diabetes mellitus among persons with hepatitis C virus infection in the United States. *Ann. Intern. Med.* 2000; **133**: 592-9.
- 9 Shintani Y, Fujie H, Miyoshi H *et al.* Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance. *Gastroenterology* 2004; **126**: 840-8.
- 10 Aytug S, Reich D, Sapiro LE *et al.* Impaired IRS-1/PI3-kinase signaling in patients with HCV: a mechanism for increased prevalence of type 2 diabetes. *Hepatology* 2003; **38**: 1384-92.
- 11 Kawaguchi T, Yoshida T, Harada M *et al.* Hepatitis C virus down-regulates insulin receptor substrates 1 and 2 through up-regulation of suppressor of cytokine signaling 3. *Am. J. Pathol.* 2004; **165**: 1499-508.
- 12 Koike K. Hepatitis C virus infection can present with metabolic disease by inducing insulin resistance. *Intervirolgy* 2006; **49**: 51-7.
- 13 Hui JM, Sud A, Farrell GC *et al.* Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression. *Gastroenterology* 2003; **125**: 1695-704.
- 14 Patton HM, Patel K, Behling C *et al.* The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients. *J. Hepatol.* 2004; **40**: 484-90.
- 15 Asselah T, Rubbia-Brandt L, Marcellin M, Negro F. Steatosis in chronic hepatitis C: why does it really matter? *Gut* 2006; **55**: 123-30.
- 16 Romero-Gomez M, Del Mar Vilorio M, Andrade RJ *et al.* Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. *Gastroenterology* 2005; **12**: 636-41.

- 17 D'Souza R, Sabin CA, Foster GR. Insulin resistance plays a role in liver fibrosis in chronic hepatitis C and in the response to antiviral therapy. *Am. J. Gastroenterol.* 2005; **100**: 1509–15.
- 18 Soresi M, Tripi S, Franco V *et al.* Impact of liver steatosis on the antiviral response in the hepatitis C virus-associated chronic hepatitis. *Liver Int.* 2006; **26**: 1119–25.
- 19 Akuta N, Suzuki F, Sezaki H *et al.* Association of amino acid substitution pattern in core protein of hepatitis C virus genotype 1b high viral load and non-virological response to interferon-ribavirin combination therapy. *Intervirology* 2005; **48**: 372–80.
- 20 Donlin MJ, Cannon NA, Yao E *et al.* Pretreatment sequence diversity differences in the full-length hepatitis C virus open reading frame correlate with early response to therapy. *J. Virol.* 2007; **81**: 8211–24.
- 21 Okanoue T, Itoh Y, Hashimoto H *et al.* Predictive values of amino acid sequences of the core and NS5A regions in antiviral therapy for hepatitis C: a Japanese multi-center study. *J. Gastroenterol.* 2009; **44**: 952–63.
- 22 Akuta N, Suzuki F, Hirakawa M *et al.* Amino acid substitutions in the hepatitis C virus core region of genotype 1b are the important predictor of severe insulin resistance in patients without cirrhosis and diabetes mellitus. *J. Med. Virol.* 2009; **81**: 1032–9.
- 23 Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. *Diabet. Med.* 1998; **15**: 539–53.
- 24 Seltzer HS, Allen EW, Herron AL Jr, Brennan MT. Insulin secretion in response to glycemic stimulus: relation of delayed initial release to carbohydrate intolerance in mild diabetes mellitus. *J. Clin. Invest.* 1967; **46**: 323–35.
- 25 Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing. Comparison with the euglycemic insulin clamp. *Diabetes Care* 1999; **22**: 1462–70.
- 26 Akuta N, Suzuki F, Kawamura Y *et al.* Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1a: amino acid substitutions in the core region and low-density lipoprotein cholesterol level. *J. Hepatol.* 2007; **46**: 403–10.
- 27 Enomoto N, Sakuma I, Asahina Y *et al.* Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. *N. Engl. J. Med.* 1996; **334**: 77–81.
- 28 Kato N, Hijikata M, Ootsuyama Y *et al.* Molecular cloning of the human hepatitis C virus genome from Japanese patients with non-A, non-B hepatitis. *Proc. Natl. Acad. Sci. U.S.A.* 1990; **87**: 9524–8.
- 29 Ichida F, Tsuji T, Omata M *et al.* New Inuyama classification; new criteria for histological assessment of chronic hepatitis. *Int. Hepatol. Commun.* 1996; **6**: 112–9.
- 30 Knodell RG, Ishak KG, Bilack WC *et al.* Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. *Hepatology* 1981; **1**: 431–5.
- 31 Kleiner DE, Brunt EM, Van Natta M *et al.* Nonalcoholic Steatohepatitis Clinical Research Network. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. *Hepatology* 2005; **41**: 1313–21.
- 32 Yasui K, Harano Y, Mitsuyoshi H *et al.* Steatosis and hepatic expression of genes regulating lipid metabolism in Japanese patients infected with hepatitis C virus. *J. Gastroenterol.* 2010; **45**: 95–104.
- 33 Powell EE, Jonsson JR, Clouston AD. Steatosis: co-factor in other liver diseases. *Hepatology* 2005; **42**: 5–13.
- 34 Perlemuter G, Sabile A, Letteron P *et al.* Hepatitis C virus core protein inhibits microsomal triglyceride transfer protein activity and very low density lipoprotein secretion: a model of viral-related steatosis. *FASEB J.* 2002; **16**: 185–94.
- 35 Moriishi K, Mochizuki R, Moriya K *et al.* Critical role of PA28g in hepatitis C virus-associated steatogenesis and hepatocarcinogenesis. *Proc. Natl. Acad. Sci. U.S.A.* 2007; **104**: 1661–6.
- 36 Jackel-Cram C, Babiuk LA, Liu Q. Up-regulation of fatty acid synthase promoter by hepatitis C virus core protein: genotype-3a core has a stronger effect than genotype-1b core. *J. Hepatol.* 2007; **46**: 999–1008.
- 37 Jhaveri R, McHutchison J, Patel K *et al.* Specific polymorphisms in hepatitis C virus genotype 3 core protein associated with intracellular lipid accumulation. *J. Infect. Dis.* 2008; **197**: 283–91.
- 38 Negro F. Hepatitis C virus-induced steatosis: an overview. *Dig. Dis.* 2010; **28**: 294–9.
- 39 Tachi Y, Katano Y, Honda T *et al.* Impact of amino acid substitutions in the hepatitis C virus genotype 1b core region on liver steatosis and hepatic oxidative stress in patients with chronic hepatitis C. *Liver Int.* 2010; **30**: 554–9.
- 40 Fukuhara T, Takeishi K, Toshima T *et al.* Impact of amino acid substitutions in the core region of HCV on multistep hepatocarcinogenesis. *Hepatol. Res.* 2010; **40**: 171–8.
- 41 Soonthornpun S, Setasuban W, Thamprasit A *et al.* Novel insulin sensitivity index derived from oral glucose tolerance test. *J. Clin. Endocrinol. Metab.* 2003; **88**: 1019–23.
- 42 Abdul-Ghani MA, Matsuda M, Balas B, DeFronzo RA. Muscle and liver insulin resistance indexes derived from the oral glucose tolerance test. *Diabetes Care* 2007; **30**: 89–94.
- 43 Kanauchi M, Nakajima M, Saito Y, Kanauchi K. Pancreatic beta-cell function and insulin sensitivity in Japanese subjects with impaired glucose tolerance and newly diagnosed type 2 diabetes mellitus. *Metabolism* 2003; **52**: 476–81.
- 44 Fartoux L, Poujol-Robert A, Guéchet J *et al.* Insulin resistance is a cause of steatosis and fibrosis progression in chronic hepatitis C. *Gut* 2005; **54**: 1003–8.
- 45 Denechaud PD, Dentin R, Girard J, Postic C. Role of ChREBP in hepatic steatosis and insulin resistance. *FEBS Lett.* 2008; **582**: 68–73.
- 46 Sumida Y, Kanemasa K, Hara T *et al.* Amino acid substitutions in the hepatitis C virus genotype1b core region are the most important predictors of liver steatosis in non-cirrhotic patients without overt diabetes independent of glucose intolerance. *Hepatology* 2010; **50** (Suppl): 744A.

Association of IL28B Variants With Response to Pegylated-Interferon Alpha Plus Ribavirin Combination Therapy Reveals Intersubgenotypic Differences Between Genotypes 2a and 2b

Naoya Sakamoto, MD, PhD,^{1,2*} Mina Nakagawa,¹ Yasuhito Tanaka,³ Yuko Sekine-Osajima,¹ Mayumi Ueyama,¹ Masayuki Kurosaki,⁴ Nao Nishida,⁵ Akihiro Tamori,⁶ Nishimura-Sakurai Yuki,¹ Yasuhiro Itsui,^{1,7} Seishin Azuma,¹ Sei Kakinuma,^{1,2} Shuhei Hige,⁸ Yoshito Itoh,⁹ Eiji Tanaka,¹⁰ Yoichi Hiasa,¹¹ Namiki Izumi,⁴ Katsushi Tokunaga,⁵ Masashi Mizokami,¹² Mamoru Watanabe¹ and the Ochanomizu-Liver Conference Study Group

¹Department of Gastroenterology and Hepatology, Tokyo Medical and Dental University, Tokyo, Japan

²Department for Hepatitis Control, Tokyo Medical and Dental University, Tokyo, Japan

³Department of Virology & Liver Unit, Nagoya City University Graduate School of Medical Sciences, Mizuho-ku Nagoya, Japan

⁴Division of Gastroenterology and Hepatology, Musashino Red Cross Hospital, Tokyo, Japan

⁵Department of Human Genetics, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan

⁶Department of Hepatology, Osaka City University Graduate School of Medicine, Osaka, Japan

⁷Department of Internal Medicine, Soka Municipal Hospital, Saitama, Japan

⁸Department of Internal Medicine, Hokkaido University Graduate School of Medicine, Sapporo, Japan

⁹Molecular Gastroenterology and Hepatology, Kyoto Prefectural University of Medicine, Kyoto, Japan

¹⁰Department of Medicine, Shinshu University School of Medicine, Matsumoto, Japan

¹¹Department of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Ehime, Japan

¹²Research Center for Hepatitis and Immunology, International Medical Center of Japan Konodai Hospital, Ichikawa, Japan

Genetic polymorphisms of the interleukin 28B (IL28B) locus are associated closely with outcomes of pegylated-interferon (PEG-IFN) plus ribavirin (RBV) combination therapy. The aim of this study was to investigate the relationship between IL28B polymorphism and responses to therapy in patients infected with genotype 2. One hundred twenty-nine chronic hepatitis C patients infected with genotype 2, 77 patients with genotype 2a and 52 patients with genotype 2b, were analyzed. Clinical and laboratory parameters, including genetic variation near the IL28B gene (rs8099917), were assessed. Drug adherence was monitored in each patient. Univariate and multivariate statistical analyses of these parameters and clinical responses were carried out. Univariate analyses showed that a sustained virological response was correlated significantly with IL28B polymorphism, as well as age, white blood cell and neutrophil counts, adherence to RBV, and rapid virological response. Subgroup analysis revealed that patients infected with genotype 2b achieved significantly lower rapid virological response rates than those with genotype 2a. Patients with the IL28B-major allele showed higher virus clearance rates at each time point

than those with the IL28B-minor allele, and the differences were more profound in patients infected with genotype 2b than those with genotype 2a. Furthermore, both rapid and sustained virological responses were associated significantly with IL28B alleles in patients with genotype

Abbreviations: HCV, hepatitis C virus; HCC, hepatocellular carcinoma; IFN, interferon; PEG-IFN, pegylated-interferon; RBV, ribavirin; IL28B, interleukin 28B; SNPs, single nucleotide polymorphisms; BMI, body mass index; ALT, alanine transaminase; ISDR, the interferon sensitivity determining region; ITPA, inosine triphosphatase

Grant sponsor: Ministry of Education, Culture, Sports, Science and Technology-Japan; Grant sponsor: Japan Society for the Promotion of Science, Ministry of Health, Labour and Welfare-Japan; Grant sponsor: Japan Health Sciences Foundation; Grant sponsor: Miyakawa Memorial Research Foundation; Grant sponsor: National Institute of Biomedical Innovation.

Naoya Sakamoto and Mina Nakagawa contributed equally to this work.

*Correspondence to: Naoya Sakamoto, MD, PhD, Department of Gastroenterology and Hepatology, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo 113-8519, Japan. E-mail: nsakamoto.gast@tmd.ac.jp

Accepted 10 January 2011

DOI 10.1002/jmv.22038

Published online in Wiley Online Library (wileyonlinelibrary.com).

2b. IL28B polymorphism was predictive of PEG-IFN plus RBV combination treatment outcomes in patients infected with genotype 2 and, especially, with genotype 2b. In conclusion, IL-28B polymorphism affects responses to PEG-IFN-based treatment in difficult-to-treat HCV patients. *J. Med. Virol.* **83:871–878, 2011.** © 2011 Wiley-Liss, Inc.

KEY WORDS: hepatitis C virus (HCV); chronic hepatitis C; genotype 2; PEG-IFN plus RBV therapy; combination therapy; IL28B; interferon- λ 3

INTRODUCTION

Hepatitis C virus (HCV) infects around 170 million people worldwide and is characterized by a high probability of developing chronic inflammation and fibrosis of the liver, leading to end-stage liver failure and hepatocellular carcinoma (HCC) [Alter, 1997; Sakamoto and Watanabe, 2009]. Since the first report in 1986, type I interferons have been the mainstay of HCV therapy [Hoofnagle, 1994]. Current standards of care consist of a combination of ribavirin (RBV) plus pegylated interferon (PEG-IFN)-alpha for 48 weeks for infection with genotypes 1 and 4, and for 24 weeks for the other genotypes [Zeuzem et al., 2000; Fried et al., 2002]. Although this treatment improved substantially sustained virological response rates, it may result also in serious adverse effects and a considerable proportion of patients require early discontinuation of treatment. Patients of African origin have even poorer treatment outcomes [Rosen and Gretch, 1999]. Given this situation, a precise assessment of the likely treatment outcomes before the initiation of treatment may improve substantially the quality of antiviral treatment.

Recently, several studies have reported that genetic polymorphisms of the IL28B locus, which encodes interferon- λ 3 (interleukin 28B), are associated with response to interferon-based treatment of chronic HCV infections with genotype 1 [Ge et al., 2009; Suppiah et al., 2009; Tanaka et al., 2009] and also spontaneous clearance of HCV [Thomas et al., 2009].

While chronic HCV infections with genotype 2 are associated with good treatment outcome, there are some refractory cases among patients infected with genotype 2, similar to genotype 1. The aims of this study were to analyze retrospectively clinical and virological factors associated with treatment response in patients with chronic HCV infection with genotype 2 who were treated with PEG-IFN plus RBV combination therapy and to clarify the relationship between IL28B polymorphism and the response to combination therapy.

PATIENTS AND METHODS

The authors analyzed retrospectively 129 patients with chronic HCV infection with genotype 2 who

received combination therapy with PEG-IFN plus RBV between December 2004 and December 2009 at 10 multicenter hospitals (liver units with hepatologists) throughout Japan. All patients had chronic active hepatitis confirmed histologically or clinically and were positive for anti-HCV antibodies and serum HCV RNA by quantitative or qualitative assays. Patients with a positive test for serum hepatitis B surface antigen, coinfection with other HCV genotypes, coinfection with human immunodeficiency virus, other causes of hepatocellular injury (such as alcoholism, autoimmune hepatitis, primary biliary cirrhosis, or a history of treatment with hepatotoxic drugs), and a need for hemodialysis were excluded.

Study Design

Each patient was treated with combination therapy with PEG-IFN- α 2b (Peg-Intron, Schering-Plough Nordic Biotech, Stockholm, Sweden, at a dose of 1.2–1.5 μ g/kg subcutaneously once a week) or PEG-IFN- α 2a (Pegasys; Roche, Basel, Switzerland, at a dose of 180 μ g subcutaneously once a week) plus RBV (Rebetol, Schering-Plough Nordic Biotech or Copegus; Roche) 600–1,000 mg daily depending on the body weight (b.w.) (b.w. <60 kg: 600 mg po daily; b.w. 60–80 kg: 800 mg po daily; b.w. >80 kg: 1,000 mg po daily; in two divided doses). The duration of the combination therapy was set at a standard 24 weeks, but treatment reduction or discontinuation was permitted by doctor's decision. The rates of PEG-IFN and RBV administration achieved were calculated as percentages of actual total dose administered of a standard total dose of 24 weeks, according to body weight before therapy. During treatment, patients were assessed as outpatients at weeks 2, 4, 6, 8, and then every 4 weeks for the duration of treatment and at every 4 weeks after the end of treatment. Biochemical and hematological testing was carried out in a central laboratory. Serum HCV RNA was measured before treatment, during treatment at 4 weekly intervals, and after therapy at 4 weekly intervals for 24 weeks, by quantitative or qualitative assays.

Patient Evaluation

The following factors were analyzed to determine whether they were related to the efficacy of combination therapy: age, gender, body mass index (BMI), previous IFN therapy, grade of inflammation and stage of fibrosis on liver biopsy, pretreatment biochemical parameters, such as white blood cells, neutrophils, hemoglobin, platelet count, alanine transaminase (ALT) level, serum HCV RNA level (log IU/ml), and single nucleotide polymorphism (SNPs) in the *IL28B* locus (rs8099917). Liver biopsy specimens were evaluated blindly, to determine the grade of inflammation and stage of fibrosis, by an independent interpreter who was not aware of the clinical data. Activity of inflammation was graded on a scale of 0–3: A0 shows no activity, A1 shows mild activity, A2 shows moderate activity and A3 shows severe activity. Fibrosis was staged on a scale of 0–4:

F0 shows no fibrosis, F1 shows moderate fibrosis, F2 shows moderate fibrosis with few septa, F3 shows severe fibrosis with numerous septa without cirrhosis and F4 shows cirrhosis.

Informed written consent was obtained from each patient who participated in the study. The study protocol conformed to the ethical guidelines of the Declaration of Helsinki and to the relevant ethical guidelines as reflected in a priori approval by the ethics committees of all the participating universities and hospitals.

SNP Genotyping

Human genomic DNA was extracted from whole blood of each patient. Genetic polymorphism of IL28B was determined by DigiTag2 assay by typing one tag SNP located within the IL28B locus, rs8099917 (22). Heterozygotes (T/G) or homozygotes (G/G) of the minor allele (G) were defined as having the IL28B minor allele, whereas homozygotes for the major allele (T/T) were defined as having the IL28B major allele.

Outcomes

The primary end point was a sustained biochemical and virological response. A sustained virological response was defined as serum HCV RNA undetectable at 24 weeks after the end of treatment. Secondary end points were a rapid virological response (HCV RNA undetectable in serum at week 4) and end-of-treatment virological response. In addition, tolerability (adverse events) and drug adherence were recorded and factors potentially associated with virological response explored.

Statistical Analysis

SPSS software package (SPSS 18J, SPSS, Chicago, IL) was used for statistical analysis. Discrete variables were evaluated by Fisher's exact probability test and distributions of continuous variables were analyzed by the Mann-Whitney *U*-test. Independent factors possibly affecting response to combination therapy were examined by stepwise multiple logistic-regression analysis. All *P*-values were calculated by two-tailed tests, and those of less than 0.05 were considered statistically significant.

RESULTS

Clinical Characteristics and Response to Therapy

The clinical characteristics and response rates to therapy of 129 patients are summarized in Tables I and II. Sixty-eight patients achieved a rapid virological response, whereas 44 patients remained HCV-RNA positive at week 4. Treatment reduction or cessation was permitted also to avoid side effects, and one patient stopped treatment at week 12 because he was

TABLE I. Baseline Characteristics of Participating Patients Infected With HCV Genotype 2

Total number	129
Genotype (2a/2b)	77/52
IL28B SNPs (rs8099917)	
TT/TG/GG	100/28/1
Age (years) ^a	64 (20–73)
Gender (male/female)	64/65
Body mass index (kg/m ²) ^a (N = 80)	23.7 (16.9–33.5)
Previous interferon therapy (no/yes)	102/21 (unknown 6)
Histology at biopsy (N = 96)	
Grade of inflammation	
A0/1/2/3	10/53/29/4
Stage of fibrosis	
F0/1/2/3	7/59/19/11
White blood cells (/μl) ^b (N = 94)	5,115 ± 1,630
Neutrophils (/μl) ^b (N = 94)	2,765 ± 1,131
Hemoglobin (g/dl) ^b (N = 95)	14.2 ± 1.3
Platelet count (×10 ⁻³ /μl) ^b (N = 98)	187 ± 95
ALT (IU/L) ^b (N = 95)	82 ± 78
Serum HCV-RNA level (log(IU/ml)) ^{a,c}	6.2 (3.6–7.4)
Treatment duration (>16, ≤24)	19/110

SNPs, single nucleotide polymorphisms; ALT, alanine transaminase.

^aData are shown as median (range) values.

^bData are expressed as mean ± SD.

^cData are shown as log(IU/ml).

anticipated to be a non-responder. On an intention-to-treat analysis, serum HCV-RNA levels were negative at the end of treatment in 125 of the 129 patients (97%) treated and, among them, 98 (76%) achieved a sustained virological response. The rapid virological response rate of patients infected with genotype 2b was lower significantly than that of patients infected with genotype 2a (*P* = 0.036) (Table II). The sustained virological response rate decreased with RBV drug discontinuation and dose reduction (84% and 66% with ≥80% and <80% of RBV dose, *P* = 0.021, Table III). Adherences to PEG-IFN did not influence a sustained virological response or end of treatment response significantly, while RBV adherence was associated significantly with a sustained virological response (Table III).

Factors Associated With a Sustained Virological Response

Next the host clinical and viral factors associated with a sustained virological response were analyzed. Univariate statistical analysis showed that six parameters were associated significantly with the sustained virological response rates, including age, white blood cells, neutrophils, adherence to RBV, rapid virological response and an IL28B SNP (rs8099917) (Table IV). There was no significant association of sustained virological response with gender, previous interferon therapy, stage of fibrosis, pretreatment HCV titer or adherence to PEG-IFN. Further multivariate analyses were conducted using significant factors identified by the univariate analysis (Table V). The multiple logistic-regression analysis showed that only a rapid virological response was associated with a sustained virological response (OR = 0.170, *P* = 0.019).

TABLE II. Response Rates to Therapy

Character	Number/total number (%)		
Overall			
RVR	68/112 (61)		
ETR	125/129 (97)		
SVR	98/129 (76)		
Genotype	2a	2b	P-value
RVR	46/67 (69)	22/45 (49)	0.036
ETR	74/77 (96)	51/52 (98)	NS
SVR	56/77 (73)	42/52 (81)	NS

RVR, rapid virological response; ETR, end of treatment response; SVR, sustained virological response. Bold indicated *P*-value of less than 0.05.

TABLE III. Response Rates to Treatment According to Drug Adherence

	≥80%	<80%	P-value
PEG-IFN adherence			
ETR	94/96 (98)	31/33 (94)	NS
SVR	75/96 (78)	23/33 (70)	NS
RBV adherence			
ETR	72/73 (99)	53/56 (95)	NS
SVR	61/73 (84)	37/56 (66)	0.021

ETR, end of treatment response; SVR, sustained virological response; PEG-IFN, pegylated interferon; RBV, ribavirin. The rates of PEG-IFN and RBV administration achieved were calculated as percentages of actual total dose administered of a standard total dose of 24 weeks, according to body weight before therapy. Bold indicated *P*-value of less than 0.05.

Comparison of Sustained Virological Response Rates According to IL28B SNPs

The PEG-IFN plus RBV treatment efficacy was compared after dividing the study subjects into two groups based on IL28B alleles (Table VI). Patients homozygous for the IL28B major allele (TT allele) achieved significantly higher rapid and sustained virological response

rates than those heterozygous or homozygous for the IL28B minor allele (TG/GG alleles) ($P < 0.05$). In addition, responses to PEG-IFN plus RBV treatment were analyzed after dividing the study subjects into those with genotype 2a and with genotype 2b. The rapid and sustained virological response rates tended to be higher in patients homozygous for the IL28B major allele than those heterozygous or homozygous for the

TABLE IV. Clinical and Virological Characteristics of Patients Based on Therapeutic Response

	SVR (n = 98)	Non-SVR (n = 31)	P-value
Genotype (2a/2b)		56/42	21/10
IL28B SNPs (rs8099917)			
TT/TG + GG	81/17	19/12	0.024
Age (years) ^a	56 (20–73)	61 (40–72)	0.002
Gender (male/female)	51/47	13/18	NS
Body mass index (kg/m ²) ^a	22.8 (16.9–33.5)	24.1 (20.3–27.6)	NS
Previous Interferon therapy (no/yes)	80/14	22/7	NS
Grade of inflammation (A0-1/2-3)	46/28	15/7	NS
Stage of fibrosis (F0-2/3-4)	64/10	21/1	NS
White blood cells (/μl) ^b	5,318 ± 1,617	4,489 ± 1,540	0.032
Neutrophils (/μl) ^b	2,913 ± 1,139	2,278 ± 983	0.021
Hemoglobin (g/dl) ^b	14.2 ± 1.4	14.1 ± 1.1	NS
Platelet count (×10 ⁻³ /μl) ^b	193 ± 105	171 ± 54	NS
ALT (IU/ml) ^b	79 ± 73	94 ± 92	NS
Pretreatment Serum HCV-RNA level (log(IU/ml)) ^{a,c}	6.1 (3.6–7.4)	6.3 (4.0–6.7)	NS
PEG-IFN adherence (≥80%/<80%)	75/23	21/10	NS
RBV adherence (≥80%/<80%)	61/37	12/19	0.024
RVR/non-RVR	57/24	11/20	0.001

SNPs, single nucleotide polymorphisms; ALT, alanine transaminase; RVR, rapid virological response.

^aData are show as median (range) values.

^bData are expressed as mean ± SD.

^cData are shown as log (IU/ml).

Bold indicated *P*-value of less than 0.05.

TABLE V. Multivariate Analysis for the Clinical and Virological Factors Related to Sustained Response With Peg-IFN Plus RBV Therapy in 63 Patients

Factor	Category	Odds ratio (95% CI)	P-value
Regression analysis			
RVR	RVR	1	0.019
	Non-RVR	0.170 (0.039–0.744)	
RBV adherence	≥80%	1	0.061
	<80%	0.250 (0.059–1.064)	
IL28B SNPs (rs8099917)	TT	1	0.104
	TG + GG	0.252 (0.048–1.330)	
Age		1.087 (0.976–1.211)	0.128
Neutrophils		0.999 (0.997–1.001)	0.209
White blood cells		1.000 (0.999–1.002)	0.504

CI, confidence interval; SNPs, single nucleotide polymorphisms; RVR, rapid virological response, RBV, ribavirin.
 Bold indicated P-value of less than 0.05.

IL28B minor allele infected with both genotype 2a and 2b, and these differences were more profound in patients infected with genotype 2b than with genotype 2a. The rapid and sustained virological response rates of patients with the major IL28B allele were higher significantly than those of patients with the minor IL28B allele infected only with genotype 2b (rapid virological response: 58% and 0% with IL28B major and hetero/minor, $P = 0.002$, sustained virological response: 88% and 44% with IL28B major and hetero/minor, $P = 0.009$).

Although the rapid virological response rate of patients infected with genotype 2b was lower significantly than that of patients infected with genotype 2a, the sustained virological response rate was higher in patients infected with genotype 2b than with genotype 2a (Table II). In order to investigate that discrepancy, sustained virological response rates in patients with or without rapid virological response were analyzed according to IL28B SNPs. In patients infected with genotype 2b and a non-rapid virological response, the sustained virological response rates differed significantly between IL28B major and hetero/minor groups (sustained virological response with non-rapid virological response: 75% and 29% with IL28B major and hetero/minor, $P = 0.044$), and no one achieved a rapid

virological response among the patients infected with genotype 2b and with the IL28B hetero/minor allele. In patients infected with genotype 2a, on the contrary, there was no significant correlation of rapid and sustained virological response rates between IL28B SNPs (sustained virological response with rapid virological response: 78% and 70% with IL28B major and hetero/minor, $P = 0.630$, sustained virological response with non-rapid virological response: 57% and 43% with IL28B major and hetero/minor, $P = 0.552$).

Next, changes in virological response rates over time were investigated in patients treated with PEG-IFN plus RBV and the time course was analyzed after separating the patients infected with genotype 2a and 2b (Fig. 1). Patients with IL28B-TG and -GG showed significantly lower rates of rapid and sustained virological response, compared to patients with IL28B-TT, and greater differences were observed according to IL28B SNPs among patients infected with genotype 2b than with 2a.

Side Effects

Side effects leading to Peg-IFN plus RBV discontinuation occurred in eight patients (6.2%) and discontinuation of RBV alone occurred in four patients (3.1%).

TABLE VI. Rapid and Sustained Virological Response Rates to Treatment According to IL28B SNPs

Character	IL28B major	IL28B hetero/minor	P-value
Number/total number (%)			
Overall			
RVR	58/88 (66)	10/24 (42)	0.031
SVR	81/100 (81)	17/29 (59)	0.013
Genotype 2a			
RVR	36/50 (72)	10/17 (59)	NS
SVR	43/57 (75)	13/20 (65)	NS
Genotype 2b			
RVR	22/38 (58)	0/7 (0)	0.002
SVR	38/43 (88)	4/9 (44)	0.009

RVR, rapid virological response; ETR, end of treatment response; SVR, sustained virological response.




Fig. 1. Changes over time in virological response rates were confirmed in patients treated with PEG-IFN plus RBV, and the time courses were analyzed after separating the patients infected with genotypes 2a and 2b. Patients with the IL28B major (TT allele) are indicated in the figure by a continuous line and those with IL28B hetero or minor (TG or GG), by a dotted line. IL28B-TG and -GG patients showed significantly lower rates of rapid and sustained virological response, compared to IL28B-TT patients. *P*-values were two-tailed and those of less than 0.05 were considered to be statistically significant. **P* < 0.01.

Among the eight patients who withdrew from both drugs, four, including one who stopped at week 7, had achieved a sustained virological response. Among four patients who withdrew from RBV alone, three had achieved a sustained virological response. The events leading to drug withdrawal were HCC treatment ($n = 2$), general fatigue ($n = 2$), retinopathy, neuro-psychiatric event, severe dermatological symptoms suggestive of the drug-induced hypersensitivity syndrome, and arrhythmia.

DISCUSSION

Recent studies suggest that genetic variations in IL28B are strongly associated with response to therapy of chronic HCV infection with genotype 1 [Ge et al., 2009; Suppiah et al., 2009; Tanaka et al., 2009] and with spontaneous HCV clearance [Thomas et al., 2009]. In this study, univariate analyses showed that the sustained virological response was correlated significantly with IL28B polymorphism (rs8099917) as well as age, adherence to RBV and rapid virological response, and multiple logistic-regression analysis showed that only a rapid virological response was associated with a sustained virological response in all patients infected with genotype 2 (Table V). Although the IL28B

polymorphisms are not so useful for predicting the clinical outcomes of PEG-IFN plus RBV combination therapy among patients with genotype 2, compared to genotype 1, IL28B polymorphism was predictive of PEG-IFN plus RBV treatment outcomes among patients with genotype 2 and, more remarkably, among patients with genotype 2b in this study. Indeed, both rapid and sustained virological response rates according to the rs8099917 genotypes were different significantly in patients with genotype 2b but not in patients with genotype 2a. Furthermore, in the plot of virological response (Fig. 1), a stronger effect of the IL28B allele was observed in patients with genotype 2b than with genotype 2a.

It has been reported that there was no significant association between genetic variation in IL28B and response to therapy of HCV patients infected with genotype 2 or 3, indicating that the prognostic value of the risk allele for treatment response might be limited to individuals with difficult-to-treat HCV genotypes [Rauch et al., 2010]. This report lacks details of the distribution of the various genotypes. The present study agrees with a more recent report that the IL28B polymorphism was associated with a sustained virological response in patients with chronic HCV infection with genotype 2 or 3 who did not achieve a rapid virological response [Mangia et al., 2010]. In Japan, the percentage of HCV infection with genotype 1b is 70%, genotype 2a is 20% and genotype 2b is 10%, whilst other genotypes are observed only rarely. In this study, the association of IL28B polymorphism with response to therapy was analyzed in more detail, considering the subtypes 2a and 2b, and IL28B polymorphism (rs8099917) found to be linked more closely to the virological response of patients infected with genotype 2b than those with genotype 2a. A recent *in vitro* study, which constructed several chimeric virus clones between HCV-2b and HCV-JFH1 (2a), also supported subgenotypic differences between genotype 2a and 2b [Suda et al., 2010]. The authors speculated that the prognostic value of the risk allele for treatment response might be more pronounced in individuals with difficult-to-treat HCV subgenotypes, such as patients infected with genotype 2b, compared with 2a. In addition, the prevalence of the IL28B minor allele is much higher in Caucasians and African Americans than in eastern Asian populations [Thomas et al., 2009], which suggest that the effects of IL28B polymorphism could be more pronounced in non-Asian populations. In the present results, however, the sustained virological response rate of patients infected with genotype 2b was higher than that of patients with genotype 2a overall. We speculate that, among patients infected with genotype 2b, only those with the IL28B minor variant might be treatment-refractory. That possibility might be validated further by a larger cohort study with genotype 2b.

The sustained virological response rates decreased significantly with failure of adherence to RBV (Table III), which was extracted as a factor associated with sustained virological response by univariate

analysis (Table IV). Regardless of the drug adherence, end of treatment response rates of patients infected with genotype 2 were around 94–99%, but the sustained virological response rates of the patients who received a total cumulative treatment dose of RBV of <80% was reduced significantly. As reported previously, increased RBV exposure during the treatment phase was associated with an increased likelihood of a sustained virological response [McHutchison et al., 2009] and these results confirm the importance of RBV in order to prevent relapse. Furthermore, host genetic variation leading to inosine triphosphatase (ITPA) deficiency protects against hemolytic anemia in chronic hepatitis C patients receiving RBV as revealed recently [Fellay et al., 2010]. We have reported also that the *ITPA* SNP, rs1127354, is confirmed to be a useful predictor of RBV-induced anemia in Japanese patients and that the incidence of early dose reduction was significantly higher in patients with *ITPA*-major (CC) variant as expected and, more importantly, that a significant higher sustained virological response rate was achieved in patients with the *ITPA*-hetero/minor (CA/AA) variant with non-genotype 1 or low viral loads [Sakamoto et al., 2010].

A rapid virological response was extracted in this study as a factor associated with sustained virological response only by multivariate analysis. It has been reported recently that a rapid virological response is an important treatment predictor and that drug adherence, which is reported to affect the therapeutic efficacy in patients infected with genotype 1, had no impact on the both sustained and rapid virological responses in combination therapy for patients infected with genotype 2 [Inoue et al., 2010]. The reasons why several host factors useful for predicting the response to therapy in patients with genotype 1, such as gender, age, progression of liver fibrosis and IL28B polymorphism had no influence on the efficacy in patients with genotype 2, can be attributed to IFN-sensitive genotypes. Similarly, the other viral factors useful for predicting the response to therapy, such as viral load and amino acid substitutions in the Core and NS5A regions had no influence on treatment outcomes. In this study, patients who achieved a rapid virological response had a high sustained virological response rate, regardless of IL28B polymorphism in patients with genotype 2a but, interestingly, none of the IL28B-TG and -GG patients with genotype 2b achieved a sustained virological response (although there were nine IL28B-TG and -GG patients with genotype 2b, two could not be determined as rapid virological response because the times at which they became HCV-negative were not recorded clearly, being described as 4–8 weeks.) These results also suggest that patients with both genotype 2b and IL28B minor allele are refractory cases.

IL28B encodes a protein also known as IFN- λ 3 [O'Brien, 2009]. *IL28A* (IFN- λ 2) and *IL29* (IFN- λ 1) are found adjacent to *IL28B* on chromosome 19. These three IFN- λ cytokines, discovered in 2003 by two independent groups [Kotenko et al., 2003; Sheppard et al.,

2003] have been suggested to be involved in the suppression of replication of a number of viruses, including HCV [Robek et al., 2005; Marcello et al., 2006; Tanaka et al., 2010]. Humans have these three genes for IFN- λ , and this group of cytokines is now collectively referred to as type III IFN [Zhou et al., 2007]. IFN- λ functionally resembles type I IFN, inducing antiviral protection in vitro [Kotenko et al., 2003; Sheppard et al., 2003] as well as in vivo [Ank et al., 2006]. Type III IFN utilizes a receptor complex different from that of type I IFN, but both types of IFN induce STAT1, STAT2, and STAT3 activation by activation of a highly overlapping set of transcription factors, and the two types of IFN seem to have similar biological effects at a cellular level. Some in vitro studies have suggested that IFN- α induces expression of IFN- λ genes [Siren et al., 2005]. Other in vitro studies also suggest that IFN- λ inhibits hepatitis C virus replication through a pattern of signal transduction and regulation of interferon-stimulated genes that is distinct from IFN- α and that the anti-HCV activity of either IFN- α or IFN- λ is enhanced by a low dose of the other [Marcello et al., 2006]. A novel mechanism of the interaction between IFN- α and IFN- λ may play a key role in the suppression of HCV [O'Brien, 2009].

In conclusion, IL28B polymorphism is predictive of PEG-IFN plus RBV treatment outcomes in patients infected with genotype 2, and more remarkably with genotype 2b. These results suggest that IL-28B polymorphism affects responses to IFN-based treatment in more difficult-to-treat subpopulations of HCV patients, and that intersubgenotypic differences between genotype 2a and 2b are revealed by responses to PEG-IFN plus RBV treatment according to IL28B variants.

ACKNOWLEDGMENTS

The study is based on 10 multicenter hospitals throughout Japan, in the Kanto area (Tokyo Medical and Dental University Hospital, Musashino Red Cross Hospital, Kashiwa City Hospital, Kudanzaka Hospital, Showa General Hospital, Tsuchiura Kyodo General Hospital, Toride Kyodo General Hospital), Tokai area (Nagoya City University Hospital, Mishima Social Insurance Hospital) and Chugoku/Shikoku area (Ehime University Hospital).

REFERENCES

- Alter MJ. 1997. Epidemiology of hepatitis C. *Hepatology* 26:62S–65S.
- Ank N, West H, Bartholdy C, Eriksson K, Thomsen AR, Paludan SR. 2006. Lambda interferon (IFN-lambda), a type III IFN, is induced by viruses and IFNs and displays potent antiviral activity against select virus infections in vivo. *J Virol* 80:4501–4509.
- Fellay J, Thompson AJ, Ge DL, Gumbs CE, Urban TJ, Shianna KV, Little LD, Qiu P, Bertelsen AH, Watson M, Warner A, Muir AJ, Brass C, Albrecht J, Sulikowski M, McHutchison JG, Goldstein DB. 2010. *ITPA* gene variants protect against anaemia in patients treated for chronic hepatitis C. *Nature* 464:405–408.
- Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncalves FL, Haussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J. 2002. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. *N Engl J Med* 347:975–982.

- Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, Heinzen EL, Qiu P, Bertelsen AH, Muir AJ, Sulkowski M, McHutchison JG, Goldstein DB. 2009. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. *Nature* 461:399–401.
- Hoofnagle JH. 1994. Therapy of acute and chronic viral hepatitis. *Adv Intern Med* 39:241–275.
- Inoue Y, Hiramatsu N, Oze T, Yakushijin T, Mochizuki K, Hagiwara H, Oshita M, Mita E, Fukui H, Inada M, Tamura S, Yoshihara H, Hayashi E, Inoue A, Imai Y, Kato M, Miyagi T, Hoshui A, Ishida H, Kiso S, Kanto T, Kasahara A, Takehara T, Hayashi N. 2010. Factors affecting efficacy in patients with genotype 2 chronic hepatitis C treated by pegylated interferon-alpha-2b and ribavirin: Reducing drug doses has no impact on rapid and sustained virological responses. *J Viral Hepat* 17:336–344.
- Kotenko SV, Gallagher G, Baurin VV, Lewis-Antes A, Shen M, Shah NK, Langer JA, Sheikh F, Dickensheets H, Donnelly RP. 2003. IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. *Nat Immunol* 4:69–77.
- Mangia A, Thompson AJ, Santoro R, Piazzolla V, Tillmann HL, Patel K, Shianna KV, Mottola L, Petruzzellis D, Bacca D, Carretta V, Minerva N, Goldstein DB, McHutchison JG. 2010. An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response. *Gastroenterology* 139:821–827.
- Marcello T, Grakoui A, Barba-Spaeth G, Machlin ES, Kotenko SV, MacDonald MR, Rice CM. 2006. Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics. *Gastroenterology* 131:1887–1893.
- McHutchison JG, Lawitz EJ, Shiffman ML, Muir AJ, Galler GW, McCone J, Nyberg LM, Lee WM, Ghalib RH, Schiff ER, Galati JS, Bacon BR, Davis MN, Mukhopadhyay P, Koury K, Noviello S, Pedicone LD, Brass CA, Albrecht JK, Sulkowski MS. 2009. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. *N Engl J Med* 361:580–593.
- O'Brien TR. 2009. Interferon-alfa, interferon-lambda and hepatitis C. *Nat Genet* 41:1048–1050.
- Rauch A, Kutalik Z, Descombes P, Cai T, di Iulio J, Mueller T, Bochud M, Battagay M, Bernasconi E, Borovicka J, Colombo S, Cerny A, Dufour JF, Furrer H, Gunthard HF, Heim M, Hirschel B, Malinverni R, Moradpour D, Mullhaupt B, Witteck A, Beckmann JS, Berg T, Bergmann S, Negro F, Telenti A, Bochud PY. 2010. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure—A genome-wide association study. *Gastroenterology* 138:1240–1243.
- Robek MD, Boyd BS, Chisari FV. 2005. Lambda interferon inhibits hepatitis B and C virus replication. *J Virol* 79:3851–3854.
- Rosen HR, Gretch DR. 1999. Hepatitis C virus: Current understanding and prospects for future therapies. *Mol Med Today* 5:393–399.
- Sakamoto N, Watanabe M. 2009. New therapeutic approaches to hepatitis C virus. *J Gastroenterol* 44:643–649.
- Sakamoto N, Tanaka Y, Nakagawa M, Yatsunami H, Nishiguchi S, Enomoto N, Azuma S, Nishimura-Sakurai Y, Kakinuma S, Nishida N, Tokunaga K, Honda M, Ito K, Mizokami M, Watanabe M. 2010. ITPA gene variant protects against anemia induced by pegylated interferon-alpha and ribavirin therapy for Japanese patients with chronic hepatitis C. *Hepatol Res* 40:1063–1071.
- Sheppard P, Kindsvogel W, Xu W, Henderson K, Schlutsmeyer S, Whitmore TE, Kuestner R, Garrigues U, Birks C, Roraback J, Ostrander C, Dong D, Shin J, Presnell S, Fox B, Haldeman B, Cooper E, Taft D, Gilbert T, Grant FJ, Tackett M, Krivan W, McKnight G, Clegg C, Foster D, Klucher KM. 2003. IL-28, IL-29 and their class II cytokine receptor IL-28R. *Nat Immunol* 4:63–68.
- Siren J, Pirhonen J, Julkunen I, Matikainen S. 2005. IFN-alpha regulates TLR-dependent gene expression of IFN-alpha, IFN-beta, IL-28, and IL-29. *J Immunol* 174:1932–1937.
- Suda G, Sakamoto N, Itsui Y, Nakagawa M, Mishima K, Onuki-Karakama Y, Yamamoto M, Funaoka Y, Watanabe T, Kiyohashi K, Nitta S, Azuma S, Kakinuma S, Tsuchiya K, Inamura M, Hiraga N, Chayama K, Watanabe M. 2010. IL-6-mediated intersubgenotypic variation of interferon sensitivity in hepatitis C virus genotype 2a/2b chimeric clones. *Virology* 407:80–90.
- Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate ML, Bassendine M, Spengler U, Dore GJ, Powell E, Riordan S, Sheridan D, Smedile A, Fragomeli V, Muller T, Bahlo M, Stewart GJ, Booth DR, George J. 2009. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. *Nat Genet* 41:1100–1104.
- Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N, Nakagawa M, Korenaga M, Hino K, Hige S, Ito Y, Mita E, Tanaka E, Mochida S, Murawaki Y, Honda M, Sakai A, Hiasa Y, Nishiguchi S, Koike A, Sakaida I, Imamura M, Ito K, Yano K, Masaki N, Sugauchi F, Izumi N, Tokunaga K, Mizokami M. 2009. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. *Nat Genet* 41:1105–1109.
- Tanaka Y, Nishida N, Sugiyama M, Tokunaga K, Mizokami M. 2010. Lambda-Interferons and the single nucleotide polymorphisms: A milestone to tailor-made therapy for chronic hepatitis C. *Hepatol Res* 40:449–460.
- Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, O'Huigin C, Kidd J, Kidd K, Khakoo SI, Alexander G, Goedert JJ, Kirk GD, Donfield SM, Rosen HR, Tobler LH, Busch MP, McHutchison JG, Goldstein DB, Carrington M. 2009. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. *Nature* 461:798–801.
- Zeuzem S, Feinman SV, Rasenack J, Heathcote EJ, Lai MY, Gane E, O'Grady J, Reichen J, Diago M, Lin A, Hoffman J, Brunda MJ. 2000. Peginterferon alfa-2a in patients with chronic hepatitis C. *N Engl J Med* 343:1666–1672.
- Zhou Z, Hamming OJ, Ank N, Paludan SR, Nielsen AL, Hartmann R. 2007. Type III interferon (IFN) induces a type I IFN-like response in a restricted subset of cells through signaling pathways involving both the Jak-STAT pathway and the mitogen-activated protein kinases. *J Virol* 81:7749–7758.

Detection of Hepatitis C Virus and Antibodies in Postmortem Blood and Bloodstains[∇]

Tomokazu Takasaka,¹ Yoshito Itoh,² Hiroto Kaneko,³ and Hiroshi Ikegaya^{1*}

Departments of Forensic Medicine¹ and Molecular Gastroenterology and Hepatology,² Graduate School of Medical Sciences, Kyoto Prefectural University of Medicine, 465 Kajii-cho, Kawaramachi-Hirokoji, Kamigyo, Kyoto 602-8566, Japan, and Aiseikai Yamashina Hospital, 19-4 Takehana Shityounocho, Yamashina-ku, Kyoto 607-8086, Japan³

Received 16 September 2010/Returned for modification 23 November 2010/Accepted 7 January 2011

To evaluate the risk of accidental hepatitis C virus (HCV) infection, we examined whether anti-HCV antibodies and HCV RNA were detectable in HCV-infected blood samples from living donors, cadavers, and bloodstains. We showed that even after blood has left the body for several days, anti-HCV antibodies and HCV RNA may persist in it.

At the scenes of crimes or accidents, bloody materials are often handled without adequate precautions against infection because most first responders are not medical specialists. This study's objective was to test whether or not such samples are no longer potentially infectious. We used hepatitis C virus (HCV) as the representative infectious agent. To simulate the types of exposures first responders might encounter, we tested whether HCV RNA and antibodies are detected in blood and bloodstains kept at room temperature for up to 60 days and from blood of actual postmortem cases up to 14 days after death.

HCV-infected blood samples were obtained with informed consent from 12 patients (8 men and 4 women; mean age, 68.5 ± 10.7 years; range, 44 to 84 years) at the University Hospital, Kyoto Prefectural University of Medicine, and at Aiseikai Yamashina Hospital. Prior to our experiments, the serum titers of HCV RNA of all samples were determined, using the COBAS TaqMan HCV assay (Roche Molecular Systems, Pleasanton, CA), to range from 5.4 to 7.0 log IU/ml (average, 6.363 ± 0.42 log IU/ml). All samples were stored at –80°C until use.

Bloodstain samples were prepared by soaking cotton buds in 0.1 ml of HCV-infected whole-blood samples (*n* = 8) for 1 min and then drying them at room temperature for up to 60 days. Samples of HCV-infected whole blood (*n* = 4) were placed in sealed 2-ml test tubes and kept at room temperature for up to 60 days. The prepared blood and bloodstain samples were analyzed at 1, 3, 9, 27, and 60 days after preparation.

The postmortem whole-blood samples were obtained between December 2008 and April 2010 from 10 forensic autopsies performed on individuals (7 men and 3 women; mean age, 52 ± 13.15 years; range, 33 to 79 years) who had tested positive for anti-HCV antibodies. These blood samples were stored at –80°C for a week before use.

Anti-HCV antibodies from the bloodstain and whole-blood samples were detected using immunochromatography with Or-

tho Quick Chaser HCV antibody (Ortho Clinical Diagnostics, Tokyo, Japan). Before testing, the bloodstain samples were soaked in 200 μl saline; 100 μl of extracted solution was analyzed using immunochromatography.

HCV RNA was extracted from 100 μl of undiluted whole blood and 100 μl of solution extracted from blood-stained materials with a QIAamp viral RNA kit (Qiagen, Hilden, Germany). The RNA was eluted in 50 μl of RNase-free water and used for genome amplification of the partial core region using reverse transcriptase PCR (RT-PCR) with a One Step RT-PCR kit (Qiagen) in 50-μl aliquots containing 1 μl RNA, 2 μl Qiagen One Step RT-PCR enzyme mix, 400 μM deoxynucleoside triphosphate (dNTP), 0.6 μM concentrations of primers 256 (5'-CGCGCGACTAGGAAGACTTC-3'; sense) and 186 (5'-ATGTACCCCATGAGGTCGGC-3'; antisense), and Qiagen One Step RT-PCR buffer supplied by the manufacturer. The amplification was performed as described by Okamoto et al. (16). Reverse transcription was performed at 50°C for 30 min. DNA polymerase was initially activated at 95°C for 15 min for PCR. PCR amplification was performed for 35 cycles at 94°C for 30 s, 55°C for 30 s, and 72°C for 1 min, followed by a final step at 72°C for 10 min. Amplification was carried out in a PC-320 thermal cycler (ASTEC, Fukuoka, Japan). The PCR product was mixed with a 6× loading buffer double dye and subjected to electrophoresis on a 1.5% agarose gel at 100 V for 30 min. The electrophoresed agarose gel was stained with ethidium bromide (0.5 μg/ml). The image from

TABLE 1. Results of anti-HCV antibody and HCV RNA detection in blood and bloodstain samples

Test sample type	No. of positive results after the following days of storage:				
	0	3	9	27	60
Anti-HCV antibody					
Bloodstain	8	8	7	7	5
Blood	4	4	4	4	4
HCV RNA					
Bloodstain	8	8	8	8	7
Blood	4	4	4	4	4

* Corresponding author. Mailing address: Department of Forensic Medicine, Graduate School of Medicine, Kyoto Prefectural University of Medicine, 465 Kajicho, Kawaramachi-Hirokoji, Kamigyo, Kyoto 602-8566, Japan. Phone: 81752515343. Fax: 81752515343. E-mail: ikegaya@koto.kpu-m.ac.jp.

[∇] Published ahead of print on 19 January 2011.

TABLE 2. Profiles of anti-HCV antibody-positive autopsy cases and HCV RNA detection results

Case	Age (yr)/sex ^a	Postmortem time (day)	Cause of death	HCV RNA	Genotype
A	52/F	1	Drowning	+	1b
B	42/F	1	Unknown	+	1b
C	33/M	1	Hypothermia	+	2a
D	52/M	1	Drug intoxication	-	
E	46/M	1	Asphyxia	-	
F	45/M	2	Hemorrhage	+	1b
G	48/M	2	Drug intoxication	+	1b
H	62/M	2	Burn	-	
I	65/F	2	Strangulation	-	
J	79/M	14	Unknown	-	

^a M, male; F, female.

the agarose gel was captured under UV transillumination on a LAS 4000 mini camera system (Fujifilm, Tokyo, Japan).

The limit of HCV detection of the RT-PCR method was 2.06 log IU/ml. This value was extrapolated from the results for five infected serum samples taken from a single serum sample (5.4 log IU/ml using the TaqMan method) that had been diluted to concentrations between $\times 100$ and $\times 1,600$. The genotype of the HCV strain was determined using the putative C gene of the HC-J4 isolate as described previously (16).

The analysis of anti-HCV antibodies and HCV RNA from 8 bloodstain samples and 4 whole-blood samples kept up to 60 days at room temperature is summarized in Table 1. On day 27, anti-HCV antibodies were detected in 7 of 8 bloodstain samples and in all 4 whole-blood samples. HCV RNA was detected in all samples. On day 60, anti-HCV antibodies were detected in 5 of 8 bloodstain samples and in all 4 whole-blood samples. HCV RNA was detected in 7 of 8 bloodstain samples and all 4 whole-blood samples.

Among the 10 anti-HCV antibody-positive autopsy blood samples, HCV RNA was detected in 5 samples (Table 2, cases A, B, C, F, and G). The genotype of the HCV isolated in case C was 2a, and that of the others was 1b.

The detection of HCV RNA and anti-HCV antibodies in these specimens does not prove that HCV could be transmitted to humans. Previous studies have demonstrated that the RNA of the entire HCV genome synthesized *in vitro* can infect chimpanzees and produce the progeny virus (10). However, although some models and tissue culture systems have been developed (e.g., replicon systems [11], JFH-1 cells [18], and immune-deficient mice [15]), infection and cultivation of wild-type HCV have not yet been successful in model systems. Therefore, we are unable to directly test whether the samples used in this study could infect human cells. Although these results do not prove that the samples were infectious, they highlight the need for first responders and law enforcement personnel to exercise caution when handling bloody materials, even if not fresh.

The results of our study may have an additional application. Recently, the number of unidentified cadavers has increased worldwide (3). The geographic distribution of various viruses has been used to determine the geographic origins of cadavers (5–9). The worldwide distribution of HCV genotypes has also been reported (1, 2, 4, 12–14, 17, 19). In the present study, all of the samples were taken from Japanese individuals, and the viral genotypes were 1b and 2a, which are commonly detected in Japan. Therefore, it may be possible to estimate the geographic origin of a cadaver or bloodstain from the HCV viral genotype, if present. Further studies are necessary to confirm this hypothesis.

We are grateful to the donors of blood samples. We thank Jiro Yasuda of the National Research Institute of Police Science for helpful discussions.

This work was supported by a Grant-in-Aid for Scientific Research C from Japan Society for the Promotion of Science (no. 22590641).

REFERENCES

- Akkarathamrongsin, S., et al. 2010. Geographic distribution of hepatitis C virus genotype 6 subtypes in Thailand. *J. Med. Virol.* 82:257–262.
- Ali, A., H. Ahmed, and M. Idrees. 2010. Molecular epidemiology of hepatitis C virus genotypes in Khyber Pakhtoonkhaw of Pakistan. *Virol. J.* 7:203.
- Cattaneo, C., et al. 2010. Unidentified bodies and human remains: an Italian glimpse through a European problem. *Forensic Sci. Int.* 195:167.e1–6.
- Farshadpour, F., M. Makvandi, A. R. Samarbafzadeh, and M. A. Jalalifar. 2010. Determination of hepatitis C virus genotypes among blood donors in Ahvaz, Iran. *J. Med. Microbiol.* 28:54–56.
- Ikegaya, H., and H. Iwase. 2004. Trial for the geographical identification using JC viral genotyping in Japan. *Forensic Sci. Int.* 139:169–172.
- Ikegaya, H., H. Iwase, C. Sugimoto, and Y. Yogo. 2002. JC virus genotyping offers a new means of tracing the origins of unidentified cadavers. *Int. J. Legal Med.* 116:242–245.
- Ikegaya, H., et al. 2008. Forensic application of Epstein-Barr virus genotype: correlation between viral genotype and geographical area. *J. Virol. Methods* 147:78–85.
- Ikegaya, H., et al. 2007. BK virus genotype distribution offers information of tracing the geographical origins of unidentified cadaver. *Forensic Sci. Int.* 173:41–46.
- Inoue, H., et al. 2010. Determination of the geographical origin of unidentified cadavers based on geographical differences in genotype of varicella-zoster virus. *J. Med. Virol.* 82:903–908.
- Kolykhalov, A. A., et al. 1997. Replication of hepatitis C by intrahepatic inoculation with transcribed RNA. *Science* 277:570–574.
- Lohmann, V., et al. 1999. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. *Science* 285:110–113.
- Mahancy, K., et al. 1994. Genotypic analysis of hepatitis C virus in American patients. *Hepatology* 20:1405–1411.
- McOmish, F., et al. 1993. Detection of three types of hepatitis C virus in blood donors: investigation of type-specific differences in serologic reactivity and rate of alanine aminotransferase abnormalities. *Transfusion* 33:7–13.
- McOmish, F., et al. 1994. Geographical distribution of hepatitis C virus genotypes in blood donors: an international collaborative survey. *J. Clin. Microbiol.* 32:884–892.
- Mercer, D. F., et al. 2001. Hepatitis C virus replication in mice with chimeric human livers. *Nat. Med.* 7:927–933.
- Okamoto, H., et al. 1992. Typing hepatitis C virus by polymerase chain reaction with type-specific primers: application to clinical surveys and tracing infectious sources. *J. Gen. Virol.* 73:673–679.
- Ramia, S., and J. Eid-Fares. 2006. Distribution of hepatitis C virus genotypes in the Middle East. *Int. J. Infect. Dis.* 10:272–277.
- Wakita, T., et al. 2005. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. *Nat. Med.* 11:791–796.
- Xu, L. Z., D. Larzul, E. Delaporte, C. Bréchet, and D. Kremsdorf. 1994. Hepatitis C virus genotype 4 is highly prevalent in central Africa (Gabon). *J. Gen. Virol.* 75:2393–2398.

Genome-wide association study identified *ITPA/DDRKG1* variants reflecting thrombocytopenia in pegylated interferon and ribavirin therapy for chronic hepatitis C

Yasuhito Tanaka^{1,2,†}, Masayuki Kurosaki^{3,†}, Nao Nishida⁴, Masaya Sugiyama^{1,2,5}, Kentaro Matsuura^{1,6}, Naoya Sakamoto⁷, Nobuyuki Enomoto⁸, Hiroshi Yatsuhashi⁹, Shuhei Nishiguchi¹⁰, Keisuke Hino¹¹, Shuhei Hige¹², Yoshito Itoh¹³, Eiji Tanaka¹⁴, Satoshi Mochida¹⁵, Masao Honda¹⁶, Yoichi Hiasa¹⁷, Asako Koike¹⁸, Fuminaka Sugauchi^{1,6}, Shuichi Kaneko¹⁶, Namiki Izumi³, Katsushi Tokunaga⁴ and Masashi Mizokami^{5,*}

¹Department of Virology and ²Liver Unit, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan, ³Division of Gastroenterology and Hepatology, Musashino Red Cross Hospital, Tokyo, Japan, ⁴Department of Human Genetics, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, ⁵The Research Center for Hepatitis and Immunology, National Center for Global Health and Medicine, Chiba, Japan, ⁶Department of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan, ⁷Department of Gastroenterology and Hepatology, Tokyo Medical and Dental University, Tokyo, Japan, ⁸First Department of Internal Medicine, University of Yamanashi, Yamanashi, Japan, ⁹Clinical Research Center, National Nagasaki Medical Center, Nagasaki, Japan, ¹⁰Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Japan, ¹¹Division of Hepatology and Pancreatology, Kawasaki Medical College, Kurashiki, Japan, ¹²Department of Internal Medicine, Hokkaido University Graduate School of Medicine, Sapporo, Japan, ¹³Molecular Gastroenterology and Hepatology, Kyoto Prefectural University of Medicine, Kyoto, Japan, ¹⁴Department of Medicine, Shinshu University School of Medicine, Matsumoto, Japan, ¹⁵Division of Gastroenterology and Hepatology, Department of Internal Medicine, Saitama Medical University, Saitama, Japan, ¹⁶Department of Gastroenterology, Kanazawa University Graduate School of Medicine, Kanazawa, Japan, ¹⁷Department of Gastroenterology and Metabolism, Ehime University Graduate School of Medicine, Ehime, Japan, and ¹⁸Central Research Laboratory, Hitachi Ltd, Kokubunji, Japan

Received February 9, 2011; Revised May 16, 2011; Accepted May 31, 2011

Hematologic abnormalities during current therapy with pegylated interferon and ribavirin (PEG-IFN/RBV) for chronic hepatitis C (CHC) often necessitate dose reduction and premature withdrawal from therapy. The aim of this study was to identify host factors associated with IFN-induced thrombocytopenia by genome-wide association study (GWAS). In the GWAS stage using 900K single-nucleotide polymorphism (SNP) microarrays, 303 Japanese CHC patients treated with PEG-IFN/RBV therapy were genotyped. One SNP (rs11697186) located on *DDRKG1* gene on chromosome 20 showed strong associations in the minor-allele-dominant model with the decrease of platelet counts in response to PEG-IFN/RBV therapy [$P = 8.17 \times 10^{-9}$; odds ratio (OR) = 4.6]. These associations were replicated in another sample set ($n = 391$) and the combined P -values reached 5.29×10^{-17} (OR = 4.5). Fine mapping with 22 SNPs around *DDRKG1* and *ITPA* genes showed that rs11697186 at the GWAS stage had a strong linkage disequilibrium with rs1127354, known as a functional variant in the *ITPA* gene. The

*To whom correspondence should be addressed at: The Research Center for Hepatitis and Immunology, National Center for Global Health and Medicine, 1-7-1 Kohnodai, Ichikawa, Chiba 272-8516, Japan. Tel: +81 473723501; Fax: +81 473754766; Email: mmizokami@hospk.ncgm.go.jp
[†]These authors contributed equally.

***ITPA*-AA/CA genotype was independently associated with a higher degree of reduction in platelet counts at week 4 ($P < 0.0001$), as well as protection against the reduction in hemoglobin, whereas the CC genotype had significantly less reduction in the mean platelet counts compared with the AA/CA genotype ($P < 0.0001$ for weeks 2, 4, 8, 12), due to a reactive increase of the platelet count through weeks 1–4. Our present results may provide a valuable pharmacogenetic diagnostic tool for tailoring PEG-IFN/RBV dosing to minimize drug-induced adverse events.**

INTRODUCTION

Chronic infection with hepatitis C virus (HCV) presents a significant health problem worldwide, with ~2.3% of the world population, i.e. more than 120–130 million people, being infected (1). Only 20–30% of HCV-infected individuals recover spontaneously. The remaining 70–80% go on to develop chronic infection, being at significant risk for progressive liver fibrosis and subsequent liver cirrhosis (LC) and hepatocellular carcinomas (HCC). Successful treatment of chronic hepatitis C (CHC) leads to a reduction of liver fibrosis stage of patients, and also prevents HCC development (2).

Antiviral treatment has been shown to improve liver histology and decrease incidence of hepatocellular carcinoma in CHC (3,4). Current therapy for CHC consists of treatment with pegylated interferon (IFN), which acts both as an antiviral and as an immunoregulatory cytokine, and ribavirin (RBV), an antiviral pro-drug that interferes with RNA metabolism (5,6). However, <50% of patients infected with HCV genotype 1 treated in this way achieve a sustained viral response (SVR) or cure of the infection (5,7). Older patients with liver fibrosis showed a significantly lower SVR rate due to poor adherence resulting from adverse events and laboratory abnormalities (8–10). In particular, hematologic abnormalities often necessitate dose reduction, and premature withdrawal from therapy in 10–14% of patients (5,11–14). New drugs and therapeutic approaches for CHC are actively developed and several candidates are in early trial phase (15,16). Given this background, effective pre-treatment screening for predictive biomarkers with the aim of evaluating possible risks over benefits of currently available treatment will avoid these side effects in patients who will not be helped by treatment, as well as reduce the substantial cost of treatment.

The completion of the Human Genome Project has led to the advent of a new era of scientific research, including a revolutionary approach: the genome-wide association study (GWAS). Several recent studies, including our study, have demonstrated marked associations between single-nucleotide polymorphisms (SNPs) within and around *IL28B* gene, which codes for IFN- λ 3 (16–21). Another recent study indicated that genetic variants of *ITPA* gene leading to inosine triphosphatase (*ITPA*) deficiency could protect against hemolytic anemia (HA) in CHC patients receiving RBV (22).

In Japan, HCV-infected patients are relatively old and some of them have had severe fibrosis (9). Thrombocytopenia is one of the critical adverse events by IFN-based therapy among liver cirrhotic patients (23), because low platelet count (PLT), i.e. <30.0 ($10^9/l$), would be a risk factor for any bleeding, as well as it would lead to poor treatment efficiency due to the initial or early dose reduction of PEG-IFN. Based on its pathogenesis, drug-induced thrombocytopenia is usually due to bone marrow

suppression, immune-mediated destruction and platelet aggregation (24). In this study, we firstly found that genetic variants in the *ITPA/DDRGK1* genes were associated with IFN-induced thrombocytopenia, and then examined the correlation between IFN-induced thrombocytopenia and RBV-induced HA in Japanese CHC patients under PEG-IFN/RBV treatment.

RESULTS

Genetic variants associated with IFN-induced thrombocytopenia

In this study, we conducted a GWAS to identify host genes associated with the decrease of platelets in response to PEG-IFN/RBV treatment in 303 Japanese HCV patients (107 patients with the decrease of PLT versus 196 patients without the decrease of PLT based on the criteria described in Materials and Methods), using a genome-wide SNP typing array (Affymetrix SNP 6.0 for 900K SNPs). The characteristics of patients for each GWAS stage and replication stage are summarized in Table 1. Figure 1 shows a genome-wide view of the single-point association data based on allele frequencies. One SNP (rs11697186) located on *DDRGK1* gene on chromosome 20 showed strong associations in the allele frequency model ($P = 8.17 \times 10^{-9}$) with the decrease of PLT in response to PEG-IFN plus RBV treatment. The association reached genome-wide level of significance [Bonferroni criterion $P < 8.40 \times 10^{-8}$ (0.05/595052)], and another SNP (rs6139030) near *ITPA* gene had a marginal significance ($P = 4.30 \times 10^{-7}$, in Table 2).

To validate the results of the GWAS stage, 22 SNPs were selected for the replication in a set of 391 Japanese HCV patients with and without platelet reduction (Supplementary Material, Table S1). The associations of the original significant SNP (rs11697186) and the marginal SNP (rs6139030) at the GWAS stage were replicated in the second set of 391 patients in the minor-allele-dominant model [$P = 5.88 \times 10^{-10}$, odds ratio (OR) = 4.6 for rs11697186; $P = 3.83 \times 10^{-10}$, OR = 4.3 for rs6139030, Table 2]. The combined P -values for both stages reached 5.29×10^{-17} (OR = 4.5; 95% CI = 3.1–6.5) and 1.33×10^{-15} (OR = 3.9; 95% CI = 2.8–5.5), respectively (Table 2).

Genetic variants associated with RBV-induced anemia

We also conducted a GWAS to identify host genes associated with a quantitative change in hemoglobin (Hb) levels from baseline to week 4 of PEG-IFN/RBV treatment in the above 303 Japanese HCV patients (94 patients with an Hb reduction of ≥ 3 g/dl at week 4 and 209 patients without Hb reduction), using a genome-wide SNP typing array (Affymetrix SNP 6.0 for 900K SNPs). Two SNPs (rs11697186 and rs6139030)

Table 1. Clinical characteristics of patients in this study

	GWAS (<i>n</i> = 303)	Replication (<i>n</i> = 391)
Age	57.4 (9.7)	56.8 (9.9)
Sex (M/F)	151/152	209/182
Weight (kg)	60.6 (10.4)	61.3 (10.7)
Body mass index	23.5 (3.1)	23.7 (4.1)
Baseline Hb (g/dl)	14.1 (1.4)	14.1 (1.4)
Baseline platelet count (10 ⁹ /l)	151.3 (54.3)	159.7 (55.0)
Baseline ALT (IU/l)	83.5 (79.4)	86.8 (71.9)
Baseline creatinine (mg/dl)	0.70 (0.15)	0.72 (0.16)
Baseline liver fibrosis (F0–2/F3–4/ ND)	153/77/73	175/59/43
rs8099917: TT/non-TT	165/138	296/95
rs1127354: AA/CA/CC	4/79/220	6/101/284
Week 4 Hb (g/dl)	11.8 (1.7)	11.9 (1.5)
Week 4 platelet count (10 ⁹ /l)	127.6 (48.2)	132.4 (51.0)
Hb reduction at week 4	–2.3 (1.4)	–2.2 (1.4)
Platelet reduction at week 4	–22.2 (38.4)	–24.7 (30.4)

located on *DDRGK1* gene and *ITPA* gene on chromosome 20 showed strong associations in the allele frequency model ($P = 3.29 \times 10^{-10}$ and $P = 2.56 \times 10^{-9}$) with Hb reduction in response to PEG-IFN plus RBV treatment (Table 3).

The above 22 SNPs were selected for the replication study and fine mapping, including rs1127354, which was reported by the US group (22) to be strongly associated with Hb reduction (Supplementary Material, Table S2). All SNPs were genotyped using the DigiTag2 assay in an independent set of 391 Japanese HCV patients with quantitative change in Hb in response to PEG-IFN/RBV treatment [137 patients with Hb reduction versus 254 patients without Hb reduction (Table 3)]. The associations of the original SNPs were replicated in the second set of 391 patients in the minor-allele-dominant model ($P = 3.86 \times 10^{-16}$, OR = 0.02 for rs11697186; $P = 6.90 \times 10^{-18}$, OR = 0.03 for rs6139030, Table 3). The combined P -values for both stages reached 9.43×10^{-25} (OR = 0.03; 95% CI = 0.01–0.08) and 2.12×10^{-25} (OR = 0.04; 95% CI = 0.02–0.09), respectively (Table 3). The rs1127354 was also strongly associated with a quantitative change in Hb in response to PEG-IFN/RBV treatment in a set of 694 Japanese HCV patients (303 patients from the GWAS stage plus the second set of 391 patients) with and without Hb reduction ($P = 4.58 \times 10^{-26}$, OR = 0.03; 95% CI = 0.01–0.08).

Fine mapping with 22 SNPs around *DDRGK1* and *ITPA* genes showed that four significant SNPs (rs11697186, rs6139030, rs1127354 and rs13830) at the GWAS stage had a strong linkage disequilibrium (LD) ($r^2 > 0.86$) within the 22.7 kb region (Fig. 2). As the rs1127354 is known as a functional variant in the *ITPA* gene that caused ITPase deficiency and protected against RBV-induced HA (22,25), the representative SNP was applied for the following detailed studies.

***ITPA/DDRGK1* variants reflect anemia and reactive increase of the platelet count**

The mean quantitative reduction of blood cells from the baseline according to the *ITPA* rs1127354 genotypes is shown in Figure 3. Patients with the rs1127354 genotypes AA and CA showed lower degree of Hb reduction at weeks 2, 4, 8 and

12 during therapy compared with those with the CC genotype ($P < 0.0001$ for weeks 2, 4, 8 and 12 in Fig. 3A). The most difference of mean Hb reduction was found at week 4 (AA/CA –1.14 versus CC –2.72). These results show that the AA and CA genotypes are significantly associated with less absolute reduction in Hb levels, especially during the early weeks of therapy, and protect against the development of severe anemia. Interestingly, the CC genotype had significantly less reduction in the mean platelet count compared with the AA/CA genotype ($P < 0.0001$ for weeks 2, 4, 8; $P = 0.019$ for week 12 in Fig. 3B), due to a reactive increase of platelet count through weeks 1–4. The most difference of mean platelet reduction was found at week 4 [AA/CA –41.2 versus CC –18.0 (10⁹/l)]. There was no difference in the neutrophil leukocyte count between genotypes (Fig. 3C). We then compared the percentage of patients with platelet count reduction in the *ITPA* rs1127354 genotypes at week 4 of PEG-IFN/RBV therapy (Fig. 4). The percentage of patients with a platelet count reduction of < 30 (10⁹/l) at week 4 was significantly higher in the rs1127354 genotypes CC ($P < 0.0001$), indicating that the degree of platelet count reduction was less in patients with the rs1127354 genotype CC. A multivariate analysis for factors associated with a platelet reduction > 30 (10⁹/l) at week 4 showed that lower platelet count at the baseline and the rs1127354 genotypes AA/CA were independently associated with platelet reduction (OR = 1.15; 95% CI = 1.11–1.20; $P < 0.0001$, OR = 5.92; 95% CI = 3.82–9.17; $P < 0.0001$, respectively).

Figure 5 showed reactive increase of the platelet count through weeks 1–4 of PEG-IFN/RBV therapy. Patients with anemia (Hb reduction ≥ 3.0 g/dl) at week 4 had a significantly higher degree of the reactive increase of the platelet count than those without anemia ($P < 0.0001$ in Fig. 5A). Within a subgroup of patients with the rs1127354 genotypes CC, patients with anemia still had a significantly higher degree of reactive increase of the platelet count than those without anemia ($P = 0.004$ in Fig. 5B). On the other hand, patients with the rs1127354 genotypes CC had a significantly higher degree of the reactive increase of the platelet count than those with genotypes AA/CA ($P < 0.0001$ in Fig. 5C), and a similar result was obtained in a subgroup of patients without anemia (Fig. 5D). To elucidate the significant factors associated with the rs1127354 genotypes by multivariate analysis, the rs1127354 genotypes AA/CA were independently associated with protection against the reduction in Hb and more reduction in platelet counts at week 4 due to a lower degree of the reactive increase of the platelet count (OR = 0.029; 95% CI = 0.009–0.092; $P < 0.0001$, OR = 4.73; 95% CI = 3.04–7.37; $P < 0.0001$, respectively). Indeed, the reactive increase of the platelet count through weeks 1–4 was positively correlated with a high platelet count at the baseline and anemia (Hb reduction ≥ 3.0 g/dl) at week 4, but was negatively correlated with rs1127354 genotypes AA/CA and a platelet count reduction of ≥ 30 (10⁹/l) at week 4 (Table 4).

Relationship between *ITPA* rs1127354 genotypes and treatment outcome due to dose reduction of PEG-IFN or RBV

In this population, a multivariate analysis showed that SVR was significantly associated with *IL28B* TT-genotype [OR




Figure 1. Genome-wide association results in 303 Japanese HCV patients with the decrease of platelets in response to PEG-IFN plus RBV treatment (107 patients with the decrease of PLT and 196 patients without the decrease of PLT). *P*-values were calculated using the χ^2 test for allele frequencies. Dots with arrow on chromosome 20 showed a significant SNP ($P = 8.17 \times 10^{-9}$ for rs11697186) and a candidate SNP with a marginal significance ($P = 4.30 \times 10^{-7}$ for rs6139030) associated with the decrease of PLT with response to PEG-IFN/RBV treatment. The dotted line indicates a genome-wide significance ($P < 8.40 \times 10^{-8}$).

Table 2. Two SNPs (rs11697186 and rs6139030) significantly associated with the decrease of PLT in response to PEG-IFN/RBV treatment

dbSNP rsID	Nearest gene	MAF ^a (allele)	Allele (1/2)	Stage	Patients with the decrease of PLT			Patients without the decrease of PLT			OR (95% CI) ^b	<i>P</i> -value ^c
					11	12	22	11	12	22		
rs11697186	<i>DDRGI1</i>	0.15 (T)	T/A	GWAS	3 (2.8)	48 (44.9)	56 (52.3)	0 (0.0)	32 (16.6)	161 (83.4)	4.6 (2.7–7.8)	8.17×10^{-9}
				Replication	3 (1.8)	65 (39.9)	95 (58.3)	3 (1.4)	25 (12.0)	181 (86.6)	4.6 (2.8–7.7)	5.88×10^{-10}
				Combined	6 (2.2)	113 (41.9)	151 (55.9)	3 (0.7)	57 (14.2)	342 (85.1)	4.5 (3.1–6.5)	5.29×10^{-17}
rs6139030	<i>ITPA</i>	0.17 (C)	T/C	GWAS	56 (52.3)	48 (44.9)	3 (2.8)	157 (80.1)	38 (19.4)	1 (0.5)	3.7 (2.2–6.1)	4.30×10^{-7}
				Replication	96 (54.9)	74 (42.3)	5 (2.9)	181 (83.8)	32 (14.8)	3 (1.4)	4.3 (2.7–6.8)	3.83×10^{-10}
				Combined	152 (53.9)	122 (43.3)	8 (2.8)	338 (82.0)	70 (17.0)	4 (1.0)	3.9 (2.8–5.5)	1.33×10^{-15}

^aMinor allele frequency and minor allele in 184 healthy Japanese individuals.

^bOR for the minor allele in a dominant model.

^c*P*-value by χ^2 test for the minor allele dominant model.

6.12 (2.78–13.46), $P < 0.0001$] as well as platelet counts [OR 1.18 (1.11–1.26), $P < 0.00001$]. We analyzed whether the rs1127354 genotype could influence the treatment outcome by PEG-IFN/RBV therapy. When analyzed in the patients available for treatment outcome (172 with *ITPA*-AA/CA and 450 with *ITPA*-CC), the percentage of patients receiving >80% of the expected PEG-IFN and RBV dose at baseline and week 4 was not significantly different among the rs1127354 genotypes. However, the rate of SVR tended to be higher in patients with *ITPA*-AA/CA genotype than those with *ITPA*-CC (48.8 versus 37.3%), because the relapse rate was lower in patients with *ITPA*-AA/CA. To investigate the influence on treatment outcome by dose reduction of PEG-IFN, in a subgroup of patients with low platelet counts (<10) at baseline (19 with *ITPA*-AA/CA and 53 with *ITPA*-CC) we analyzed the treatment outcome according to

rs1127354 genotypes. The SVR rate was very low in each group (21.1% in *ITPA*-AA/CA and 17.0% in *ITPA*-CC), because many patients had the initial dose reduction of PEG-IFN (<80% of standard dose)—36.8% of patients with *ITPA*-AA/CA and 44.6% of patients with *ITPA*-CC genotype. Further prospective studies are required among the pre-cirrhotic or cirrhotic patients with low platelet counts.

DISCUSSION

Recent genome-wide association studies, including our study on HCV infection, have identified two important host genetic variants: the SNP in *IL28B* gene, which is strongly associated with response to therapy for chronic genotype 1 HCV infection (16–21), and the SNP in *ITPA* gene, which precisely predicts RBV-induced anemia in

Table 3. Two SNPs (rs11697186 and rs6139030) significantly associated with quantitative change in Hb levels from baseline to week 4 of PEG-IFN/RBV treatment

dbSNP rsID	Nearest gene	MAF ^a (allele)	Allele (1/2)	Stage	Patients with quantitative change in Hb			Patients without quantitative change in Hb			OR (95% CI) ^b	P-value ^c
					11	12	22	11	12	22		
rs11697186	<i>DDRGK1</i>	0.15 (T)	T/A	GWAS	0 (0.0)	3 (3.3)	89 (96.7)	3 (1.5)	77 (37.0)	128 (61.5)	0.06 (0.02–0.16)	3.29×10^{-10}
				Replication	0 (0.0)	2 (1.5)	134 (98.5)	6 (2.5)	88 (37.3)	142 (60.2)	0.02 (0.01–0.09)	3.86×10^{-16}
				Combined	0 (0.0)	5 (2.2)	223 (97.8)	9 (2.0)	165 (37.2)	270 (60.8)	0.03 (0.01–0.08)	9.43×10^{-25}
rs6139030	<i>ITPA</i>	0.17 (C)	T/C	GWAS	88 (93.6)	6 (6.4)	0 (0.0)	125 (59.8)	80 (38.3)	4 (1.9)	0.08 (0.03–0.22)	2.56×10^{-9}
				Replication	134 (97.8)	3 (2.2)	0 (0.0)	143 (56.3)	103 (40.6)	8 (3.1)	0.03 (0.01–0.08)	6.90×10^{-18}
				Combined	222 (96.1)	9 (3.9)	0 (0.0)	268 (57.9)	183 (39.5)	12 (2.6)	0.04 (0.02–0.09)	2.12×10^{-25}

^aMinor allele frequency and minor allele in 184 healthy Japanese individuals.

^bOR for the minor allele in a dominant model.

^cP-value by χ^2 square test for the minor allele dominant model.




Figure 2. Pairwise LD (r^2) diagrams for *DDRGK1* and *ITPA*. Lower panel shows estimates of pairwise r^2 for 22 SNPs selected in the replication study using the second set of 391 Japanese HCV patients with and without quantitative change in PLT levels from baseline to week 4 of PEG-IFN/RBV treatment.

European-American population (22) and Japanese population (26). The genetic variation of *ITPA* causing an accumulation of inosine triphosphate (ITP) has been shown to protect patients against RBV-induced anemia during treatment for

CHC infection. A recent report showed the biologic mechanism that ITP confers protection against RBV-induced ATP reduction by substituting for erythrocyte GTP, which is depleted by RBV, in the biosynthesis of ATP (25).




Figure 3. *ITPA* rs1127354 genotypes and the quantitative reduction of blood cells from baseline. Mean reduction of (A) Hb levels, (B) platelet counts and (C) neutrophil leukocyte counts during treatment according to rs1127354 genotype is shown. Solid and dotted lines indicate patients with CC and AA/CA genotypes, respectively. Error bars indicate standard error. CC genotype had more reduction in mean Hb levels during therapy compared with the AA/CA genotype (* $P < 0.0001$ for weeks 2, 4, 8, 12). CC genotype had less of a reduction in mean platelet counts (* $P < 0.0001$ for weeks 2, 4, 8, and ** $P = 0.019$ for week 12), and showed a reactive increase of platelet counts through weeks 1–4.




Figure 4. *ITPA* rs1127354 genotypes and reduction of platelet counts at week 4 of PEG-IFN/RBV therapy. The percentage of patients with platelet count reduction of >50 ($10^9/l$) (black bar), 30–50 ($10^9/l$) (gray bar) and <30 ($10^9/l$) (white bar) at week 4 is shown for rs1127354 genotypes. The incidence of platelet count reduction of >50 and <30 was significantly lower in patients with the rs1127354 genotypes CC compared with AA/CA genotypes: 12 versus 35%, $P < 0.0001$, and 69 versus 31%, $P < 0.0001$, respectively.

In this study, two SNPs, rs11697186 and rs6139030, which were within and around *DDRGK1* gene on chromosome 20, were strongly associated with thrombocytopenia as well as

with Hb reduction at week 4. In clinical practice, the positive predictive value and negative predictive value by rs11697186 genotypes were 66.5 and 69.4% for thrombocytopenia, as well as 97.2 and 45% for RBV-induced anemia at week 4. As previously reported (22,26), a functional SNP (rs1127354) in the *ITPA* locus, which is in strong LD with rs11697186, was the most significant SNP associated with RBV-induced anemia and, in this study, IFN-induced thrombocytopenia in Japanese genetic populations. Note that severe Hb decline, which is mainly found in ITPA-CC patients, was inversely correlated with platelet reduction. This would contribute to an association between severe anemia and relative reactive increase of platelet count in this population, which attenuated the IFN effect on the platelet count. Our data supported a previous report which described that the current use of RBV, inducing severe anemia, might blunt the thrombocytopenic effect of IFNs as a result of reactive increase of platelet counts (27).

A previous paper showed hematological and bone marrow effects of RBV in rhesus monkeys (28). Hb values decreased significantly during RBV administration due to dose-related erythroid hypoplasia in bone marrow and returned to normal following withdrawal. On the other hand, increase of the platelet count occurred in both low- and high-dose treatment groups during RBV administration, with a fall of the platelet count to normal after drug withdrawal. The effect on platelet count was clearly dose related, with maximum counts rising to twice and three times above baseline levels in the low- and high-dose groups, respectively. This caused a significant increase of




Figure 5. Reactive increase of platelet counts through weeks 1–4. Box plots of reactive increase of platelet count through weeks 1–4 according to the degree of anemia at week 4 are shown for all patients (A) and a subgroup of patients with the rs1127354 genotypes CC (B). Patients with anemia (Hb reduction ≥ 3.0 g/dl) at week 4 had a significantly higher degree of reactive increase of platelet count than those without anemia ($P < 0.0001$). Box plots of reactive increase of platelet counts according to the rs1127354 genotype CC are shown for all patients (C) and a subgroup of patients without anemia (D) (Hb reduction < 3.0 g/dl) at week 4. Patients with the rs1127354 genotypes CC had a significantly high degree of reactive increase of platelet counts compared with those with genotypes AA/CA ($P < 0.0001$).

Table 4. Multivariate analysis of factors associated with reactive increase of platelets ≥ 20 ($10^9/l$) through weeks 1–4

	OR	95% CI	P-value
Baseline platelet counts	1.168	1.101–1.239	< 0.0001
ITPA AA/CA	0.379	0.168–0.856	0.0196
Platelet reduction ≥ 30 ($10^9/l$) at week 4	0.051	0.021–0.120	< 0.0001
Hb reduction ≥ 3.0 g/dl at week 4	1.602	0.914–2.809	0.0996

the platelet count associated with increased numbers of megakaryocytes. Additionally, the sequence homology of thrombopoietin (TPO) and erythropoietin (EPO) may explain the synergy of the physiologic role of TPO and EPO in platelet production. When EPO is elevated, as in iron deficiency anemia, an amino acid sequence similar to TPO may increase the platelet count (29).

Another possibility is a direct association between *ITPA* SNPs or the related SNPs with a strong LD and IFN-induced thrombocytopenia. *DDRGL1* (DDRGL domain-containing protein 1) is a novel C53/LZAP-interacting protein. C53/LZAP (also named as Cdk5rap3) is a putative tumor suppressor that plays important roles in multiple cell signaling pathways, including DNA damage response and NF- κ B signaling (30); however, it remains largely unknown how the function of *DDRGL1* variants is regulated. Further studies are required to elucidate the possible association between *DDRGL1* variants and thrombocytopenia.

Multivariate analysis demonstrated that rs1127354 in the *ITPA* gene was independently associated with RBV-induced severe anemia and IFN-induced thrombocytopenia. This finding suggests that rs1127354 would be a useful marker to predict these hematological side effects by PEG-IFN/RBV therapy, indicating that genetic testing of *ITPA* variant might be applied to establish personalized dosages of PEG-IFN/RBV therapy. The rate of SVR tended to be higher in patients with *ITPA*-AA/CA genotype than those

with *ITPA*-CC in this population. This might reflect decreased treatment efficacy (higher relapse rate) due to dose reduction of RBV in patients with *ITPA*-CC genotype. Our recent paper also demonstrated that the incidence of early dose reduction was significantly higher in *ITPA*-major (CC) patients as expected and, more importantly, that a significantly higher SVR rate was achieved in *ITPA*-hetero/minor (CA/AA) patients with HCV non-1b or low viral load strains (31) and in a subset of Japanese patients with the favorable TT genotype at rs8099917 of *IL28B* (32). Taken together, our results indicate that the *ITPA* minor variant A is not only a protective allele against PEG-IFN and RBV treatment-associated anemia in Japanese population, but also a significant predictor of SVR in certain HCV strains that show good response to IFN. The possible mechanism of protection against RBV-induced hemolysis is that ITP deficiency or low-activity variants (*ITPA* minor variant A) in turn lead to the accumulation of ITP in red blood cells (33,34), and the ITP confers protection against RBV-induced ATP reduction by substituting for erythrocyte GTP (25). On the other hand, half of the *ITPA*-major (CC) patients did not develop a significant Hb decline. This finding suggests other low-frequency *ITPA* variants or SNPs in other enzymes that are involved in erythrocyte purine nucleoside metabolism.

In Japan, the older HCV-infected patients developing liver fibrosis have been prevalent (mean age 62 years) (9). Thrombocytopenia by PEG-IFN/RBV therapy could lead to poor treatment efficiency among such Japanese patients with LC due to the initial or early dose reduction of PEG-IFN. In fact, $\sim 40\%$ of such population in this study had the initial dose reduction of PEG-IFN, resulting in a low SVR rate. Splenectomy or embolization of the splenic artery might be one of the options to increase the SVR rate, but a sufficient treatment outcome had not been obtained at present (35). Based on the recently accumulated SNP data, if patients had favorable *IL28B* genotype and *ITPA*-CC (lower reduction of platelet counts), a standard dose of PEG-IFN might be available for

the patients with lower platelet counts and the SVR rate might be increased due to sufficient dose of PEG-IFN.

Several STAT-C agents (specifically targeted antiviral therapies for hepatitis C) are being tested for clinical efficacy against hepatitis C (12,13,15,16). Most experts believe that when new drugs are approved to treat hepatitis C, they will be used in combination with PEG-IFN and RBV. Moreover, recent clinical trials, including NS3 protease inhibitors, have shown that PEG-IFN plus RBV would be necessary to achieve optimal treatment responses (12,13). Our present results may provide a valuable pharmacogenetic diagnostic tool for tailoring PEG-IFN and RBV dosing to minimize drug-induced adverse events and for further optimization of clinical anti-HCV chemotherapeutics.

MATERIALS AND METHODS

Patients

From April 2007 to April 2010, samples were obtained from 303 patients with chronic HCV (genotype 1) infection who were treated at 14 multi-center hospitals (liver units with hepatologists) throughout Japan. Each patient was treated with PEG-IFN- α 2b (1.5 μ g/kg body weight, subcutaneously once a week) or PEG-IFN- α 2a (180 μ g once a week) plus RBV (600–1000 mg daily according to body weight) for 48 weeks. Treatment duration was extended in some patients up to 72 weeks, according to the physicians' preferences. The dose of PEG-IFN or RBV was reduced according to the recommendations on the package inserts or the clinical conditions of the individual patients. EPO or other growth factors were not given. Written informed consent was obtained from each patient and the study protocol conformed to the ethics guidelines of the Declaration of Helsinki and was approved by the institutional ethics review committees. HBsAg-positive and/or anti-HIV-positive patients were excluded from this study.

In the following stage of replication study, SNP genotyping in an independent set of 391 Japanese HCV patients treated with PEG-IFN plus RBV treatment was completed using the DigiTag2 or TaqMan assay (ABI) following the manufacturer's protocol. The characteristics of patients for each GWAS stage and replication stage are summarized in Table 1.

SNP genotyping and data cleaning

In the GWAS stage, we genotyped 303 Japanese HCV patients with and without the decrease of platelet counts from baseline to week 4 of PEG-IFN/RBV treatment [107 patients with a decrease of >30 ($10^9/l$) in platelet counts and 196 patients without a decrease of >30 ($10^9/l$) in platelet counts], using the Affymetrix Genome-Wide Human SNP Array 6.0 according to the manufacturer's instructions. The cut-off value was calculated to maximize the difference, which was also close to the median change. The average overall call rate of patients with and without the decrease of PLT reached 98.69 and 98.72%, respectively. We then applied the following thresholds for SNP QC in data cleaning: SNP call rate $\geq 95\%$ for all samples, MAF $\geq 1\%$ for all samples. A total of 595 052 SNPs on autosomal chromosomes passed the QC filters and were used for association analysis. All cluster

plots of SNPs showing $P < 0.0001$ in association analyses by comparing allele frequencies in both groups with and without the decrease of PLT were checked by visual inspection, and SNPs with ambiguous genotype calls were excluded.

In the following stage of the replication study and high-density association mapping, we selected 23 tag SNPs from the 44.7 kb region, including *DDRGK1* gene and *ITPA* gene by analyzing LD and haplotype structure based on the HapMap data of Japanese, using the Haploview software. Of these tag SNPs, rs1127354 within the *ITPA* gene, which was associated with RBV-induced anemia (22), was included; however, rs7270101 was excluded because recent papers studying Japanese patients showed no variants in rs7270101 (26,31,32). The SNP genotyping in an independent set of 391 Japanese HCV patients with and without quantitative change in PLT levels from baseline to week 4 of PEG-IFN/RBV treatment (175 patients with quantitative change in PLT and 216 patients without quantitative change in PLT) was completed using the DigiTag2 assay (36). Twenty-two of the 23 SNPs were successfully analyzed and were used for SNP genotyping and data cleaning. All 22 SNPs in the replication study cleared HWE P -value > 0.001 .

Based on the above SNPs data obtained from 303 Japanese HCV patients, using the Affymetrix Genome-Wide Human SNP Array 6.0, we also performed GWAS between 94 patients with a quantitative change of >3 g of reduction in Hb and 209 patients without quantitative change in Hb levels from baseline to week 4 of PEG-IFN/RBV treatment. SNP genotyping in an independent set of 391 Japanese HCV patients with and without quantitative change in Hb levels from baseline to week 4 of PEG-IFN/RBV treatment (137 patients with quantitative change in Hb and 254 patients without quantitative change in Hb) was also completed using the DigiTag2 assay (36). Twenty-two of the 23 SNPs were successfully analyzed and were used for SNP genotyping and data cleaning.

An application of the Cochran–Armitage test on all the SNPs showed the genetic inflation factor $\lambda = 1.000$ for thrombocytopenia and $\lambda = 1.006$ for anemia in the GWAS stage (Supplementary Material, Figs S1 and S2). In addition, principal component analysis was performed in 303 samples for the GWAS stage together with the HapMap samples (CEU, YRI, CHB and JPT) (Supplementary Material, Fig. S3). These results implied that the effect of population stratification was negligible, except one sample, which was excluded from further analysis.

Laboratory and histological tests

Blood samples were obtained at baseline, 1, 2, 4, 8 and 12 weeks after the start of therapy and for hematologic tests after the start of therapy and for hematologic tests, blood chemistry and HCV-RNA. Genetic polymorphism in the *IL28B* gene (rs8099917) was determined using the ABI TaqMan assay (Applied Biosystems, Carlsbad, CA, USA). Fibrosis was evaluated on a scale of 0–4 according to the METAVIR scoring system. The SVR was defined as an undetectable HCV-RNA level by qualitative PCR with a lower detection limit of 50 IU/ml (Amplicor, Roche Diagnostic Systems, CA, USA) or by Cobas Ampliprep/Cobas TaqMan assay (CAP/CTM) with a lower detection limit of